FY2025 EPS Estimates for VRTX Lowered by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has revised down its FY2025 earnings per share (EPS) estimate for Vertex Pharmaceuticals from $15.64 to $15.57, maintaining an "Overweight" rating with a target price of $485.00.
• Other analysts, including Guggenheim and Stifel Nicolaus, have also adjusted their target prices for Vertex, showing mixed sentiments with ratings ranging from "buy" to "hold."
• Vertex Pharmaceuticals reported earnings of $4.52 per share for the last quarter, surpassing analysts' expectations, and its revenue increased by 11.3% year-over-year.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) - Research analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for Vertex Pharmaceuticals in a research report issued on Thursday, October 9th. Cantor Fitzgerald analyst C. Gould now forecasts that the pharmaceutical company will earn $15.57 per share for the year, down from their previous forecast of $15.64. Cantor Fitzgerald currently has a "Overweight" rating and a $485.00 target price on the stock. The consensus estimate for Vertex Pharmaceuticals' current full-year earnings is $15.63 per share.

VRTX has been the topic of a number of other reports. Guggenheim decreased their target price on Vertex Pharmaceuticals from $558.00 to $546.00 and set a "buy" rating on the stock in a research note on Wednesday, August 6th. Wall Street Zen cut shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Friday, August 22nd. Raymond James Financial initiated coverage on shares of Vertex Pharmaceuticals in a report on Tuesday, September 2nd. They issued a "market perform" rating on the stock. Weiss Ratings reissued a "hold (c+)" rating on shares of Vertex Pharmaceuticals in a report on Wednesday, October 8th. Finally, Stifel Nicolaus decreased their price target on shares of Vertex Pharmaceuticals from $494.00 to $455.00 and set a "hold" rating on the stock in a report on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have issued a Hold rating to the company's stock. According to MarketBeat, Vertex Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $494.38.

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals stock opened at $407.79 on Monday. The stock has a market cap of $104.55 billion, a P/E ratio of 29.15 and a beta of 0.43. The firm's fifty day moving average price is $393.91 and its 200-day moving average price is $438.74. Vertex Pharmaceuticals has a fifty-two week low of $362.50 and a fifty-two week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, topping analysts' consensus estimates of $4.24 by $0.28. The business had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. Vertex Pharmaceuticals's revenue was up 11.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($12.83) EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS.

Insider Activity at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs purchased 5,000 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, August 6th. The shares were acquired at an average cost of $389.68 per share, for a total transaction of $1,948,400.00. Following the transaction, the director directly owned 45,000 shares in the company, valued at $17,535,600. The trade was a 12.50% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.20% of the company's stock.

Institutional Trading of Vertex Pharmaceuticals

Large investors have recently modified their holdings of the business. Activest Wealth Management bought a new stake in shares of Vertex Pharmaceuticals during the 1st quarter valued at about $25,000. Clal Insurance Enterprises Holdings Ltd boosted its stake in shares of Vertex Pharmaceuticals by 450.0% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock valued at $27,000 after purchasing an additional 45 shares in the last quarter. Access Investment Management LLC bought a new stake in Vertex Pharmaceuticals during the 2nd quarter valued at approximately $27,000. Legacy Investment Solutions LLC bought a new stake in Vertex Pharmaceuticals during the 2nd quarter valued at approximately $29,000. Finally, Flaharty Asset Management LLC bought a new stake in Vertex Pharmaceuticals during the 1st quarter valued at approximately $32,000. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.